H.C. Wainwright & Co. Believes Keryx Biopharmaceuticals Remains Undervalued

By: via Benzinga
In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $19.00 price target on Keryx ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.